BPA Call 36E79720A0015-36C24121F0125
Award Date
3/10/21
Potential Completion Date
1/31/22
Potential Value
$45K
Federal Agency
Veterans Integrated Service Network 1
Awardee
Janssen Biotech Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Chelsea, ME 04330, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for BALVERSA (erdafitinib), an oncology medication, provided by Janssen Biotech Inc. (doing business as Centocor Ortho Biotech Inc.) to the Department of Veterans Affairs (VA). The $11,317.97 firm fixed price contract is a Blanket Purchase Agreement (BPA) call order under Janssen's $3.7 million single-award BPA established in August 2020, which allows VA buying offices to efficiently procure BALVERSA and other oncology drugs. Janssen also holds a $3.1 billion...
This federal contract award is for the supply of BALVERSA (erdafitinib), a cancer treatment medication, to the Department of Veterans Affairs (VA) through the Veterans Health Administration (VHA). The prime contractor is Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a pharmaceutical manufacturer that specializes in biologic therapies. The contract is a Blanket Purchase Agreement (BPA) established in August 2020, with a ceiling value of $3.7 million and a period of...
This federal contract award to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., is for the delivery of the chemotherapy drug BALVERSA (erdafitinib) to the U.S. Department of Veterans Affairs (VA) and its Veterans Health Administration (VHA). The contract was awarded against Janssen's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB), with a ceiling value of $33,080.49. This firm fixed price delivery order will support the VHA's Veterans...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) has awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., to provide the chemotherapy drug BALVERSA (erdafitinib) for patient care. The $17,642.94 delivery order was issued against Janssen's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has a period of performance through May 7, 2024 and was awarded on May 2,...
This is a firm fixed price delivery order awarded by the Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., to provide BALVERSA (erdafitinib), an oncology medication, to the VA's Veterans Health Administration (VHA). The $15,090.62 delivery order was issued on an emergency basis to the pharmaceutical manufacturer under a $3.7 million Blanket Purchase Agreement (BPA) established in 2020, which allows VHA buying offices to efficiently...
This is a firm fixed price delivery order contract awarded to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., by the Department of Veterans Affairs (VA). The contract has an ultimate completion date of November 22, 2024 and a ceiling value of $13,639.07. The contract is for the provision of the oncology drug BALVERSA (erdafitinib) to support healthcare services for veterans through the VA's Veterans Health Administration (VHA). Janssen Biotech is a major pharmaceutical...
This is a federal contract award to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., a pharmaceutical manufacturer, to provide BALVERSA 4 MG, a cancer treatment drug, to the U.S. Department of Veterans Affairs (VA). The contract is a delivery order with a firm fixed price of $17,642.95 and an ultimate completion date of August 13, 2024. This award is associated with two larger contract vehicles - a $3.7 million single-award Blanket Purchase Agreement (BPA) established in...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) has awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the supply of the chemotherapy drug BALVERSA (erdafitinib). This order is issued against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a $3.1 billion multiple award schedule that allows VHA to procure prescription drugs. The potential value of this specific...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a firm fixed price delivery order to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc., for the chemotherapy drug BALVERSA (erdafitinib). This order was placed against Janssen's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract, a $3.1 billion multiple award schedule that allows VHA to procure prescription drugs to support veteran healthcare programs. The $22,053.66...
This is a firm fixed price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Janssen Biotech Inc., doing business as Centocor Ortho Biotech Inc. The order is valued at $18,125.50 and provides the VA's Veterans Health Administration (VHA) with the oncology medication BALVERSA (erdafitinib) to support healthcare services for veterans. The delivery order is placed against Janssen Biotech's existing $3.1 billion Federal Supply Schedule (FSS) contract for Pharmaceuticals and...